Acute myocardial infarction in a 24 year-old man possibly associated with sibutramine use

被引：16

作者：

Eroglu, Elif ^{[1
]}

Gemici, Gokmen ^{[1
]}

Bayrak, Fatih ^{[1
]}

Kalkan, Ali Kemal ^{[1
]}

Degertekin, Muzaffer ^{[1
]}

机构：

[1] TC Yeditepe Univ Hosp, Dept Cardiol, TR-34752 Istanbul, Turkey

来源：

INTERNATIONAL JOURNAL OF CARDIOLOGY | 2009年 / 137卷 / 02期

关键词：

Acute myocardial infarction; Obesity; Sibutramine; Noradrenaline; ACUTE RISK-FACTORS; WEIGHT-LOSS; SAFETY; EFFICACY; TRIGGERS; OBESITY;

D O I：

10.1016/j.ijcard.2008.06.017

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Sibutramine is an anti-obesity drug, which acts by inhibiting neuronal re-uptake of noradrenaline and serotonin. Although the most frequently seen effect of sibutramine on cardiovascular system is an increase in blood pressure and pulse rate, rare but severe side effects such as sibutramine-induced ventricular arrhythmias, heart failure and cardiovascular disease-related death are also reported. We describe a 24 year-old man with low atherosclerotic risk profile who had acute myocardial infarction possibly associated with sibutramine use. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

引用

页码：E43 / E45

页数：3

共 14 条

[1] The efficacy and safety of sibutramine for weight loss - A systematic review [J].

Arterburn, DE ;

Crane, PK ;

Veenstra, DL .

ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (09) :994-1003

[2] Myocardial infarction induced by appetite suppressants in Malaysia [J].

Azarisman, Shah M. ;

Magdi, Yahya A. ;

Noorfaizan, Saidin ;

Oteh, Maskon .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (18) :1873-1874

[3] Ethical authorship and publishing [J].

Coats, Andrew J. S. .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2009, 131 (02) :149-150

[4]

Coulter DM, 2000, PHARMACOEPIDEM DR S, V9, P273, DOI 10.1002/1099-1557(200007/08)9:4<273::AID-PDS512>3.0.CO

[5]

2-T

[6] Acute risk factors for myocardial infarction [J].

Culic, Viktor .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2007, 117 (02) :260-269

[7]

FLORENTIN M, 2007, OBES REV 1123

[8] Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity [J].

Gokcel, A ;

Gumurdulu, Y ;

Karakose, H ;

Ertorer, EM ;

Tanaci, N ;

Tutuncu, NB ;

Guvener, N .

DIABETES OBESITY & METABOLISM, 2002, 4 (01) :49-55

[9] QT interval prolongation associated with sibutramine treatment [J].

Harrison-Woolrych, M ;

Clark, DWJ ;

Hill, GR ;

Rees, MI ;

Skinner, JR .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 61 (04) :464-469

[10] Effect of sibutramine on weight maintenance after weight loss:: a randomised trial [J].

James, WPT ;

Astrup, A ;

Finer, N ;

Hilsted, J ;

Kopelman, P ;

Rössner, S ;

Saris, WHM ;

Van Gaal, LF .

LANCET, 2000, 356 (9248) :2119-2125

← 1 2 →